Heidelberg Immunotherapeutics

Heidelberg ImmunoTherapeutics GmbH was founded as a spin-off from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital in 2016. We are a biopharmaceutical company focusing on the clinical development of innovative, antibody-based immunotherapeutics for the treatment of viral diseases and cancer. Our lead first product, HDIT101, is being developed for the treatment of herpes simplex virus (HSV) infections, which are affecting several million people worldwide. Oral and genital herpes are the most common conditions. In some patients, herpes simplex infections lead to severe complications and even a life-threatening disease progression. A particular challenge is the treatment of herpes simplex viruses resistant to common antivirals.